These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35860996)

  • 1. Prognostic factors, disease course, and treatment efficacy in Duchenne muscular dystrophy: A systematic review and meta-analysis.
    Weber FJ; Latshang TD; Blum MR; Kohler M; Wertli MM
    Muscle Nerve; 2022 Oct; 66(4):462-470. PubMed ID: 35860996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of effects of continued corticosteroid treatment on cardiac and pulmonary function in non-ambulatory males with Duchenne muscular dystrophy from MD STARnet.
    Butterfield RJ; Kirkov S; Conway KM; Johnson N; Matthews D; Phan H; Cai B; Paramsothy P; Thomas S; Feldkamp ML
    Muscle Nerve; 2022 Jul; 66(1):15-23. PubMed ID: 34994466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interventions for preventing and treating cardiac complications in Duchenne and Becker muscular dystrophy and X-linked dilated cardiomyopathy.
    Bourke JP; Bueser T; Quinlivan R
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD009068. PubMed ID: 30326162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review.
    Szabo SM; Salhany RM; Deighton A; Harwood M; Mah J; Gooch KL
    Orphanet J Rare Dis; 2021 May; 16(1):237. PubMed ID: 34022943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy.
    Kim S; Zhu Y; Romitti PA; Fox DJ; Sheehan DW; Valdez R; Matthews D; Barber BJ;
    Neuromuscul Disord; 2017 Aug; 27(8):730-737. PubMed ID: 28645460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy.
    Barber BJ; Andrews JG; Lu Z; West NA; Meaney FJ; Price ET; Gray A; Sheehan DW; Pandya S; Yang M; Cunniff C
    J Pediatr; 2013 Oct; 163(4):1080-4.e1. PubMed ID: 23866715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of steroids and angiotensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance.
    Hor KN; Mazur W; Taylor MD; Al-Khalidi HR; Cripe LH; Jefferies JL; Raman SV; Chung ES; Kinnett KJ; Williams K; Gottliebson WM; Benson DW
    J Cardiovasc Magn Reson; 2011 Oct; 13(1):60. PubMed ID: 22011358
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect and safety of treatment with ACE-inhibitor Enalapril and β-blocker metoprolol on the onset of left ventricular dysfunction in Duchenne muscular dystrophy - a randomized, double-blind, placebo-controlled trial.
    Dittrich S; Graf E; Trollmann R; Neudorf U; Schara U; Heilmann A; von der Hagen M; Stiller B; Kirschner J; Pozza RD; Müller-Felber W; Weiss K; von Au K; Khalil M; Motz R; Korenke C; Lange M; Wilichowski E; Pattathu J; Ebinger F; Wiechmann N; Schröder R;
    Orphanet J Rare Dis; 2019 May; 14(1):105. PubMed ID: 31077250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocardial Fibrosis Progression in Duchenne and Becker Muscular Dystrophy: A Randomized Clinical Trial.
    Silva MC; Magalhães TA; Meira ZM; Rassi CH; Andrade AC; Gutierrez PS; Azevedo CF; Gurgel-Giannetti J; Vainzof M; Zatz M; Kalil-Filho R; Rochitte CE
    JAMA Cardiol; 2017 Feb; 2(2):190-199. PubMed ID: 27926769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment.
    Mitelman O; Abdel-Hamid HZ; Byrne BJ; Connolly AM; Heydemann P; Proud C; Shieh PB; Wagner KR; Dugar A; Santra S; Signorovitch J; Goemans N; ; McDonald CM; ; Mercuri E; ; Mendell JR
    J Neuromuscul Dis; 2022; 9(1):39-52. PubMed ID: 34420980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of survival analysis between surgical and non-surgical treatments in Duchenne muscular dystrophy scoliosis.
    Yang JH; Kim KS; Lee GH; Kim HS
    Spine J; 2020 Nov; 20(11):1840-1849. PubMed ID: 32535073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised placebo-controlled trial of combination ACE inhibitor and beta-blocker therapy to prevent cardiomyopathy in children with Duchenne muscular dystrophy? (DMD Heart Protection Study): a protocol study.
    Bourke JP; Watson G; Muntoni F; Spinty S; Roper H; Guglieri M; Speed C; McColl E; Chikermane A; Jayawant S; Adwani S; Willis T; Wilkinson J; Bryant A; Chadwick T; Wood R; Bushby K;
    BMJ Open; 2018 Dec; 8(12):e022572. PubMed ID: 30573480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of cardiac medications on ventricular function in patients with Duchenne muscular dystrophy-related cardiomyopathy.
    Murphy AP; Johnson A; Straub V; Heads-Baister A; Lord S; Bourke JP
    Muscle Nerve; 2021 Aug; 64(2):163-171. PubMed ID: 34050938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy.
    Viollet L; Thrush PT; Flanigan KM; Mendell JR; Allen HD
    Am J Cardiol; 2012 Jul; 110(1):98-102. PubMed ID: 22463839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy-analysis of registry data.
    Porcher R; Desguerre I; Amthor H; Chabrol B; Audic F; Rivier F; Isapof A; Tiffreau V; Campana-Salort E; Leturcq F; Tuffery-Giraud S; Ben Yaou R; Annane D; Amédro P; Barnerias C; Bécane HM; Béhin A; Bonnet D; Bassez G; Cossée M; de La Villéon G; Delcourte C; Fayssoil A; Fontaine B; Godart F; Guillaumont S; Jaillette E; Laforêt P; Leonard-Louis S; Lofaso F; Mayer M; Morales RJ; Meune C; Orlikowski D; Ovaert C; Prigent H; Saadi M; Sochala M; Tard C; Vaksmann G; Walther-Louvier U; Eymard B; Stojkovic T; Ravaud P; Duboc D; Wahbi K
    Eur Heart J; 2021 May; 42(20):1976-1984. PubMed ID: 33748842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological therapy for the prevention and management of cardiomyopathy in Duchenne muscular dystrophy: A systematic review.
    El-Aloul B; Altamirano-Diaz L; Zapata-Aldana E; Rodrigues R; Malvankar-Mehta MS; Nguyen CT; Campbell C
    Neuromuscul Disord; 2017 Jan; 27(1):4-14. PubMed ID: 27815032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional trajectories before and after loss of ambulation in Duchenne muscular dystrophy and implications for clinical trials.
    McDonald CM; Signorovitch J; Mercuri E; Niks EH; Wong B; Fillbrunn M; Sajeev G; Yim E; Dieye I; Miller D; Ward SJ; Goemans N;
    PLoS One; 2024; 19(6):e0304099. PubMed ID: 38829874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional abilities, respiratory and cardiac function in a large cohort of adults with Duchenne muscular dystrophy treated with glucocorticoids.
    Schiava M; Lofra RM; Bourke JP; Díaz-Manera J; James MK; Elseed MA; Malinova M; Michel-Sodhi J; Moat D; Ghimenton E; Mccallum M; Díaz CFB; Mayhew A; Wong K; Richardson M; Tasca G; Eglon G; Eagle M; Turner C; Heslop E; Straub V; Bettolo CM; Guglieri M
    Eur J Neurol; 2024 Jun; 31(6):e16267. PubMed ID: 38556893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.